Drug interference transfusion testing

Overcome pan agglutination interference associated with oncology therapies with Grifols cutting-edge technology. Not currently approved for use in the USA

Monoclobal antibody therapies that interfere with IH testing makes complex testing hard.

Create a clearer clinical picture with cutting-edge technology that unlocks monoclonal antibody therapy interference.

For oncology patients with hematologic malignancies low red blood cell counts during therapy mean multiple transfusions become their norm.

Grifols sCD38

Managing blood delivery to oncology patients on monoclonal antibody therapies can be challenging for your lab.

You can create a clearer clinical picture without lengthy procedures using Grifols soluble recombinant protein technology that blocks therapeutic monoclonal antibodies that cause pan-agglutination.

Simplify testing on patients on daratumumab therapy that interferes with results by adding Grifols sCD38 to your pretransfusion testing.

Rapid and easy to use Grifols sCD38 is a soluble recombinant protein that blocks anti-CD38 antibodies.